Fig. 7: Schematic model for GSK3α-promoted and ARIH1-mediated PD-L1 degradation.
From: ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
GSK3α phosphorylates PD-L1 at Ser279 and Ser283. This phosphorylation promotes the binding of PD-L1 with ARIH1, leading to PD-L1 ubiquitination and proteasomal degradation. This image was created by the first author.
